Inhibition of hepatitis viral replication by siRNA

Jian Wu, Kiran Mayi Nandamuri

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Small interfering RNA (siRNA)-mediated sequence-specific gene silencing is a powerful tool to inhibit endogenous and exogenous gene expression, and it holds great potential to prevent and eradicate viral infection, for which existing therapy is inadequate, such as HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). A number of studies have documented the effectiveness of siRNA against HBV or HCV at various regions of the viral genome in infected human hepatoma cell lines. Selected siRNA may reduce the production of viral replicons, as well as structural or non-structural proteins by > 90%. Only a few in vivo studies that demonstrated the efficacy of siRNA in the suppression of HBV replication in mice are available. Thus, reliable models of HBV and HCV infection in small animals or non-human primates are needed to evaluate the delivery and efficacy of siRNA as a therapeutic modality for viral hepatitis.

Original languageEnglish (US)
Pages (from-to)1649-1659
Number of pages11
JournalExpert Opinion on Biological Therapy
Issue number10
StatePublished - Oct 2004


  • Antisense
  • Hepatitis B virus
  • Hepatitis C virus
  • Ribozyme
  • Small interfering RNA

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology


Dive into the research topics of 'Inhibition of hepatitis viral replication by siRNA'. Together they form a unique fingerprint.

Cite this